3:52 PM
 | 
May 02, 2019
 |  BC Extra  |  Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

Biogen's ALS candidate reduces SOD1 protein levels in CSF
Biogen Inc. (NASDAQ:BIIB) will present on May 7 at the American Academy of Neurology meeting the interim Phase I/II data of tofersen that had prompted it to exercise an option to the amyotrophic lateral sclerosis candidate from Ionis Pharmaceuticals Inc. (NASDAQ:IONS). Among ALS patients with a confirmed SOD1 mutation, 100 mg tofersen (formerly BIIB067) significantly reduced SOD1 protein levels in CSF from baseline to week...

Read the full 343 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >